Rail RVSN Business Model Review Q3 2023 EPS Beats Forecasts ALDX Aldeyra Therapeutics Inc reports narrower Q4 2025 loss than forecast topping consensus EPS estimates by 60 percent Haoxi HAO Stock Resistance Test Investors Pile In 20260418